Disitamab vedotin is an ADC consisting of a HER2-directed antibody and Monomethyl auristatin E (MMAE). Disitamab vedotin targets HER2 protein on tumors, recognizes and penetrates cancer cells with high precision, and releases the small molecule cytotoxic drug to kill the cancer cell. The ADC is used for the study of various cancers.